Dec 23, 2009 7:30am EST Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target
Sep 17, 2009 9:19am EDT Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
Jul 23, 2009 6:00pm EDT R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Jul 23, 2009 12:00pm EDT Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
